Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
111819743 | 11181974 | 3 | F | 20160802 | 20160802 | 20150611 | 20160915 | PER | US-ASTELLAS-2015US015664 | ASTELLAS | 64.91 | YR | M | Y | 0.00000 | 20160915 | MD | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
111819743 | 11181974 | 1 | PS | XTANDI | ENZALUTAMIDE | 1 | Oral | 160 MG (40 MG X 4 CAPSULES), ONCE DAILY | 1507023PC | 203415 | 160 | MG | CAPSULE | QD | |||||
111819743 | 11181974 | 2 | SS | LUPRON | LEUPROLIDE ACETATE | 1 | Unknown | UNK, UNKNOWN FREQ. | U | 0 | FORMULATION UNKNOWN |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
111819743 | 11181974 | 1 | Prostate cancer |
111819743 | 11181974 | 2 | Product used for unknown indication |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
111819743 | 11181974 | Drug ineffective | |
111819743 | 11181974 | Dysphagia | |
111819743 | 11181974 | Hot flush | |
111819743 | 11181974 | Myalgia | |
111819743 | 11181974 | Product size issue | |
111819743 | 11181974 | Prostatic specific antigen increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
111819743 | 11181974 | 1 | 20150210 | 0 |